Drugs / BREZIVAPTAN
BREZIVAPTAN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02448212 | May 2015 → Jan 2016 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05439603 | Sep 2022 → Aug 2023 | major depressive disorder | Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03093025 | Jul 2017 → Nov 2018 | major depressive disorder | Taisho Pharmaceutical R&D Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-30 | Taisho Pharmaceutical Co., Ltd. | 選択的バソプレシンV1b受容体拮抗薬「TS-121」の全世界における独占的開発・製造・販売権に関する契約締結 taisho.co.jp ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BREZIVAPTAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314910 ↗ |
| Known as | ANC-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05439603 ↗ |
| Known as | THY-1773 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314910 ↗ |
| Known as | TS-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02448212 ↗ |
| Modality | Small molecule | — CHEMBL5314910 ↗ |
| Route | Oral | “Oral” NCT02448212 ↗ |